← All trials
NCT04518293
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 26, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- Aug 19, 2020
- Last posted
- Oct 12, 2021
- Enrollment
- 1500
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- George Medicines PTY LimitedLead sponsor
- University of New South WalesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.